Definiens AG Opens Up Shop in Boston

Company Growth in Tissue Phenomics® Prompts Expansion in U.S. Market

MUNICH--(BUSINESS WIRE)--Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the opening of its second location in the U.S. as a result of the company’s growth and expansion in North America. The office, based in Boston, MA, will be managed by Dr. Thomas Nifong, Executive Vice President, Predictive Tests and houses Definiens’ Tissue Phenomics service team, bioinformatics and customer support for North America.

“We selected Boston specifically due to its close proximity to a large number of clients, as well as the extraordinary talent pool in the area.”

This is the company’s first new office opening since its acquisition by MedImmune in 2014. Over the last year Definiens has expanded its Tissue Phenomics and Biomarker Datafication Services offerings, which enable scientists to better identify biomarkers, develop predictive tests and advance personalized medicine in oncology. The company is now working with the majority of the world’s largest pharmaceutical companies as well as a growing number of academic medical centers, comprehensive cancer centers and biotech companies in North America.

“Definiens has grown substantially over the last year, and while the need for additional office space was clear, the company also recognized a need to be located near many of the top pharma companies to enable ease of collaboration,” said Thomas Heydler, CEO, Definiens. “We selected Boston specifically due to its close proximity to a large number of clients, as well as the extraordinary talent pool in the area.”

The Boston office will be the primary location for Definiens project managers and services team to execute upon biomarker and companion diagnostic development projects in North America, expanding the company’s capacity outside of the Munich headquarters. In addition to the team it currently has in place, the new location will recruit Data Analysts, Biostatisticians, Consultants, and commercially focused employees to meet growing customer demand.

To learn more about Definiens, visit www.definiens.com.

About Definiens

Definiens is the pioneering provider of Tissue Phenomics^® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens’ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.

Help employers find you! Check out all the jobs and post your resume.